NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market Tuesday that its fiscal first quarter revenues grew by 9 percent from the year-ago quarter, beating analysts' consensus top-line estimate. 

The molecular diagnostics firm brought in total revenues of $183.5 million for the three months ended Sept. 30, compared to $168.8 million in Q1 2015, and above the consensus Wall Street estimate of $177.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.